Lisata Therapeutics, Inc. (LSTA) |
|
3 -0.08 (-2.6%)
|
03-24 15:00 |
|
Open: |
3.01 |
Pre. Close: |
3.08 |
|
High:
|
3.095 |
Low:
|
3 |
|
Volume:
|
3,180 |
Market Cap:
|
24(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:27:46 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 3.96 One year: 4.29 |
| Support: |
Support1: 2.94 Support2: 2.44 |
| Resistance: |
Resistance1: 3.39 Resistance2: 3.68 |
| Pivot: |
3.3  |
| Moving Average: |
MA(5): 3.13 MA(20): 3.27
MA(100): 3.37 MA(250): 5.76 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 13.5 %D(3): 24 |
| RSI: |
RSI(14): 36.3 |
| 52-week: |
High: 11.69 Low: 2.35 |
| Average Vol(K): |
3-Month: 13 (K) 10-Days: 6 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ LSTA ] has closed above bottom band by 2.7%. Bollinger Bands are 21% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.12 - 3.15 |
3.15 - 3.16 |
|
Low:
|
2.94 - 2.98 |
2.98 - 3 |
|
Close:
|
2.96 - 3.02 |
3.02 - 3.06 |
|
Company Description |
|
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. |
Headline News |
Thu, 23 Mar 2023
Lisata Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, March 30, 2023, at 4:30 p.m. Eastern Time - Yahoo Finance
Mon, 06 Mar 2023
Lisata Therapeutics to Webcast Live at the Life Sciences Investor ... - GlobeNewswire
Thu, 23 Feb 2023
Carvana Co reports results for the quarter ended in December ... - Kalkine Media
Thu, 02 Feb 2023
Avalo Therapeutics stock slides 20% after hours on stock and ... - Seeking Alpha
Mon, 09 Jan 2023
Ractigen Therapeutics Announces the Appointment of Harri Järveläinen as Chief Operating Officer - Yahoo Finance
Thu, 10 Nov 2022
Lisata Therapeutics Reports Third Quarter 2022 Financial Results ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
8 (M) |
| Shares Float |
7 (M) |
|
% Held by Insiders
|
2.3 (%) |
|
% Held by Institutions
|
10.5 (%) |
|
Shares Short
|
41 (K) |
|
Shares Short P.Month
|
48 (K) |
Stock Financials |
|
EPS
|
-12.98 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
9.15 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-19 |
|
Return on Equity (ttm)
|
-64.7 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-3.5 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-19 (M) |
|
Levered Free Cash Flow
|
-12 (M) |
Stock Valuations |
|
PE Ratio
|
-0.24 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0.32 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-1.23 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
